Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.

Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer intensifies. This ...

We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Tuesday. Metsera rallied to a new all-time high on Tuesday ...

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...